Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson's disease clinical trial

• Three infusions of allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) over 18-week intervals were associated with a significant annual increase in eGFR (3.29 mL/min/1.73 m²) in older adults with Parkinson's disease and preserved renal function, compared to declines in placebo and two-infusion groups. • Serum creatinine levels decreased by 0.12 mg/dL at both weeks 40 and 88 in the three-infusion group versus placebo, with high posterior probabilities (93.9% and 86.2%, respectively), indicating a potential renoprotective effect. • The study provides preliminary evidence that repeated allo-hMSC infusions may mitigate age-related kidney function decline, possibly through immunomodulatory mechanisms, but results are specific to PD and require validation in broader aging populations. • No significant differences in blood urea nitrogen (BUN) levels were observed between treatment and placebo groups, suggesting that the observed benefits are specific to eGFR and creatinine measures.